Regeneron | Pushing the Bounds of Science
Discover how Regeneron (NASDAQ: REGN) harmonizes biology and technology to create life-changing medicines. Join our team and explore clinical trials.
FDA authorizes REGEN-COV mAb for prevention for COVID-19
Dec 23, 2024 · REGEN-COV consists of the monoclonal antibodies casirivimab and imdevimab, administered together. Monoclonal antibodies are laboratory-made proteins that mimic the immune …
Regeneron Pharmaceuticals - Wikipedia
Regeneron has developed aflibercept, a VEGF inhibitor, and rilonacept, an interleukin-1 blocker. VEGF is a protein that normally stimulates the growth of blood vessels, and interleukin-1 is a protein that is …
Regen-Cov (Casirivimab and Imdevimab Injection): Side Effects, Uses ...
Apr 29, 2024 · Treatment of overdose should consist of general supportive measures including monitoring of vital signs and observation of the clinical status of the patient. There is no specific …
Effectiveness of REGEN-COV antibody combination in preventing …
REGEN-COV, a combination of the monoclonal antibodies casirivimab and imdevimab, has been approved as a treatment for high-risk patients infected with SARS-CoV-2 within five days of their …
What Was the REGEN-COV COVID-19 Antibody Treatment?
Jul 9, 2025 · REGEN-COV was a therapy developed by Regeneron Pharmaceuticals composed of two monoclonal antibodies, casirivimab and imdevimab, administered together. The primary purpose of …
Regeneron's immune disorder therapy improves daily functions in trial
Aug 26, 2025 · Regeneron Pharmaceuticals said on Tuesday its experimental therapy met the late-stage main goal of helping patients with a rare immune disorder significantly improve their daily functions …
REGEN-COV (casirivimab and imdevimab): What is it and is it FDA ...
Dec 16, 2024 · Current FDA approval status, regulatory history, and clinical trial results for REGEN-COV (Regeneron antibody cocktail), an investigational treatment for COVID-19 from the development …
REGEN-COV Antibody Combination and Outcomes in Outpatients …
Sep 29, 2021 · In the phase 1–2 portion of an adaptive trial, REGEN-COV, a combination of the monoclonal antibodies casirivimab and imdevimab, reduced the viral load and number of medical …
REGEN-COV: Uses, Side Effects, Dosage & Reviews - GoodRx
Jan 22, 2022 · REGEN-COV is a combination of two monoclonal antibodies, casirivimab and imdevimab. Casirivimab and imdevimab bind to receptors on the COVID-19 virus, which blocks the virus from …